Efficacy of the apitherapy in the treatment of recalcitrant localized plaque psoriasis and evaluation of tumor necrosis factor-alpha (TNF-α) serum level: A double-blind randomized clinical trial
- 30 December 2014
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 26 (4), 335-339
- https://doi.org/10.3109/09546634.2014.990411
Abstract
No universal consensus about optimal modality for treating the recalcitrant localized plaque psoriasis (RLPP) is available. To evaluate the immunological and clinical therapeutic effect of using apitherapy in the treatment of RLPP. Randomized 50 patients with RLPP received apitherapy (n = 25) and placebo (n = 25) every week. Both treatments were injected into lesions at weekly intervals for a maximum of 12 treatments. Following up was 6 months later. Tumor necrosis factor-alpha (TNF-α) level was measured at pre-study and at 12th week. A significant difference was found between the therapeutic responses of RLPP to the apitherapy and placebo groups (p<0.001). In the apitherapy group, complete response was achieved in 92% of patients. There was statistically significant decrease in TNF-α in the apitherapy group compared to the placebo group. No recurrence was observed in the apitherapy group. Apitherapy is effective and a safe treatment for recalcitrant localized plaque psoriasis, when other topical or physical therapies have failed.Keywords
This publication has 12 references indexed in Scilit:
- Bee Stings—A Remedy for Postherpetic Neuralgia? A Case ReportRegional Anesthesia & Pain Medicine, 2007
- Efficacy of the pulsed dye laser in the treatment of localized recalcitrant plaque psoriasis: a comparative studyBritish Journal of Dermatology, 2006
- A clinician's paradigm in the treatment of psoriasisJournal of the American Academy of Dermatology, 2005
- Serum Levels of TNF-, IFN-, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease SeverityMediators of Inflammation, 2005
- Antiarthritic effect of bee venom: Inhibition of inflammation mediator generation by suppression of NF‐κB through interaction with the p50 subunitArthritis & Rheumatism, 2004
- The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safetyDermatologic Clinics, 2004
- Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authorsJournal of the American Academy of Dermatology, 2003
- Inhibition of COX-2 activity and proinflammatory cytokines (TNF-α and IL-1β) production by water-soluble sub-fractionated parts from bee (Apis mellifera) venomArchives of Pharmacal Research, 2003
- Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisJournal of the American Academy of Dermatology, 2003
- Immunity at the surface: Homeostatic mechanisms of the skin immune systemLife Sciences, 1996